Soc. Generale Knock-Out MRK/ DE000CL9DRC7 /
18/06/2024 12:09:41 | Chg.-0.180 | Bid12:40:08 | Ask12:40:08 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
6.680EUR | -2.62% | 6.690 Bid Size: 10,000 |
6.700 Ask Size: 10,000 |
MERCK KGAA O.N. | 103.6434 - | 31/12/2078 | Call |
GlobeNewswire
09:00
Precision-Panc Team Open the PRIMUS-006 Study, a Novel Combination of IMM-101, Gemcitabine and Pembr...
GlobeNewswire
17/06
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Design...
GlobeNewswire
03/06
Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, ...
GlobeNewswire
29/05
Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio fo...
GlobeNewswire
07/05
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination wi...
GlobeNewswire
06/05
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Person...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA